PT1362600E - Utilização tópica de iscos de nf-kb para o tratamento da dermatite atópica - Google Patents

Utilização tópica de iscos de nf-kb para o tratamento da dermatite atópica Download PDF

Info

Publication number
PT1362600E
PT1362600E PT02711351T PT02711351T PT1362600E PT 1362600 E PT1362600 E PT 1362600E PT 02711351 T PT02711351 T PT 02711351T PT 02711351 T PT02711351 T PT 02711351T PT 1362600 E PT1362600 E PT 1362600E
Authority
PT
Portugal
Prior art keywords
decoy
decoys
stat
atopic dermatitis
topical use
Prior art date
Application number
PT02711351T
Other languages
English (en)
Portuguese (pt)
Inventor
Ryuichi Morishita
Motokuni Aoki
Toshio Ogihara
Yasufumi Kaneda
Hiroshige Nakamura
Original Assignee
Anges Mg Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anges Mg Inc filed Critical Anges Mg Inc
Publication of PT1362600E publication Critical patent/PT1362600E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT02711351T 2001-02-20 2002-02-06 Utilização tópica de iscos de nf-kb para o tratamento da dermatite atópica PT1362600E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001044350 2001-02-20

Publications (1)

Publication Number Publication Date
PT1362600E true PT1362600E (pt) 2008-07-09

Family

ID=18906362

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02711351T PT1362600E (pt) 2001-02-20 2002-02-06 Utilização tópica de iscos de nf-kb para o tratamento da dermatite atópica

Country Status (11)

Country Link
US (2) US9012417B2 (enExample)
EP (2) EP1690544B1 (enExample)
JP (2) JP3778357B2 (enExample)
AT (1) ATE390938T1 (enExample)
CY (1) CY1108165T1 (enExample)
DE (1) DE60225899T2 (enExample)
DK (1) DK1362600T3 (enExample)
ES (1) ES2307733T3 (enExample)
PT (1) PT1362600E (enExample)
TW (1) TWI308492B (enExample)
WO (1) WO2002066070A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69435100D1 (de) * 1993-10-29 2008-06-26 Brigham & Womens Hospital Therapeutische verwendung von cis-element-fallen in vivo
PT1362600E (pt) 2001-02-20 2008-07-09 Anges Mg Inc Utilização tópica de iscos de nf-kb para o tratamento da dermatite atópica
DE10148886A1 (de) * 2001-10-04 2003-04-30 Avontec Gmbh Inhibition von STAT-1
WO2004110533A1 (ja) * 2003-05-09 2004-12-23 Anges Mg, Inc. 薬剤が収容された針無注射器
WO2005004913A1 (ja) * 2003-07-09 2005-01-20 Anges Mg, Inc. デコイを含む薬学的組成物およびその使用方法
AU2004268457A1 (en) * 2003-08-29 2005-03-10 Anges Mg, Inc. Gene therapy for skin disorders using needleless syringes
US7378509B2 (en) * 2003-12-02 2008-05-27 Anesiva, Inc. NF-kappaB oligonucleotide decoy molecules
WO2005084180A2 (en) 2003-12-19 2005-09-15 University Of Cincinnati Polyamides and polyamide complexes for delivery of oligonucleotide decoys
EP1799271A4 (en) * 2004-09-21 2010-05-05 Anesiva Inc DISPOSAL OF POLYNUCLEOTIDES
ATE509100T1 (de) 2004-10-22 2011-05-15 Anges Mg Inc Chimäre (doppel-) attrappe
US20060258604A1 (en) * 2005-05-10 2006-11-16 Warren Strober Compositions and methods for the treatment of inflammatory bowel disease utilizing NF-kappaB decoy polynucleotides
US20090214630A1 (en) * 2005-05-10 2009-08-27 Warren Strober Compositions and Methods for the Treatment of Inflammatory Bowel Disease Utilizing NF-KappaB Decoy Polynucleotides
CA2614295A1 (en) * 2005-06-06 2006-12-14 Anges Mg, Inc. Transcription factor decoy
US20100035793A1 (en) * 2005-07-27 2010-02-11 Cheh Peng Lim Modulators
CA2634291A1 (en) * 2005-12-22 2007-06-28 Institut De Cardiologie De Montreal Transcription factor decoy oligodeoxynucleotides having multiple cis elements
JPWO2007072909A1 (ja) 2005-12-22 2009-06-04 アンジェスＭｇ株式会社 新規オリゴヌクレオチド及びそれから成るＮＦ−κＢデコイ
JP4602298B2 (ja) * 2006-08-31 2010-12-22 ホソカワミクロン株式会社 医薬製剤
US20100105762A1 (en) 2007-02-16 2010-04-29 Ryuichi Morishita Therapeutic agent for periodontal disease and alveolar bone loss due to surgery
US20080249044A1 (en) * 2007-04-03 2008-10-09 Masaya Tanaka Nucleic acid external skin formulation
DK2158316T3 (en) 2007-05-11 2015-07-20 Adynxx Inc Gene expression and pain
WO2009119836A1 (ja) * 2008-03-28 2009-10-01 アンジェスＭｇ株式会社 転写因子デコイを有効成分とする外用剤組成物
RU2668136C2 (ru) 2012-05-10 2018-09-26 Эйдинкс, Инк. Композиции для доставки активных ингредиентов
JP6705807B2 (ja) 2014-08-15 2020-06-03 エーダイニクス インコーポレイテッド 疼痛を治療するためのオリゴヌクレオチドデコイ

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2361756A (en) * 1942-03-31 1944-10-31 George W Fiero Ointments and the like
JPS56135416A (en) * 1980-03-27 1981-10-22 Mitsubishi Chem Ind Ltd Pharmaceutical preparation for skin
US4301145A (en) * 1980-07-28 1981-11-17 Cestari Joseph E Antiseptic skin cream
US6410516B1 (en) * 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
JPH05331066A (ja) * 1992-05-25 1993-12-14 Toko Yakuhin Kogyo Kk 尋常性ざ瘡治療用組成物
DE69435100D1 (de) * 1993-10-29 2008-06-26 Brigham & Womens Hospital Therapeutische verwendung von cis-element-fallen in vivo
US6399376B1 (en) * 1993-11-05 2002-06-04 Isis Pharmaceuticals, Inc. Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
US5869088A (en) * 1994-10-24 1999-02-09 Nikken Chemicals Co., Ltd Transdermal administration preparation of a 9-aminocyclopenta (b) quinoline
ATE357922T1 (de) * 1995-05-12 2007-04-15 Anges Mg Inc Heilung und vorbeugung von durch nf-kappab verursachten erkrankungen
CA2236825A1 (en) * 1995-11-21 1997-05-29 Icn Pharmaceuticals, Inc. Inhibition of tumor growth by antisense oligonucleotides for il-8 and il-8 receptor
AU731909B2 (en) * 1997-07-01 2001-04-05 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
JP2001055331A (ja) 1999-06-11 2001-02-27 Toyama Chem Co Ltd アトピー性皮膚炎治療剤
CN100542614C (zh) * 2000-02-02 2009-09-23 安增子摩祺株式会社 用于基因转移的病毒包膜载体
DE10049549A1 (de) 2000-10-06 2002-05-02 Markus Hecker Modulation der Transkription pro-inflammatorischer Genprodukte
PT1362600E (pt) 2001-02-20 2008-07-09 Anges Mg Inc Utilização tópica de iscos de nf-kb para o tratamento da dermatite atópica
JPWO2003063911A1 (ja) * 2002-02-01 2006-01-19 アンジェスＭｇ株式会社 デコイを含む薬学的組成物およびその使用方法
JP4971609B2 (ja) 2004-08-27 2012-07-11 アンジェスＭｇ株式会社 核酸皮膚外用製剤
JP2006111591A (ja) 2004-10-15 2006-04-27 Anges Mg Inc 核酸医薬を標的特異的に細胞内送達するための製剤

Also Published As

Publication number Publication date
EP1362600A1 (en) 2003-11-19
DE60225899T2 (de) 2009-04-09
EP1690544A3 (en) 2012-03-07
US9012417B2 (en) 2015-04-21
CY1108165T1 (el) 2014-02-12
EP1690544B1 (en) 2017-09-13
EP1362600A4 (en) 2005-09-21
ATE390938T1 (de) 2008-04-15
EP1362600B1 (en) 2008-04-02
JP2009102428A (ja) 2009-05-14
JPWO2002066070A1 (ja) 2004-06-17
JP3778357B2 (ja) 2006-05-24
ES2307733T3 (es) 2008-12-01
US20090105183A1 (en) 2009-04-23
WO2002066070A1 (fr) 2002-08-29
EP1690544A2 (en) 2006-08-16
TWI308492B (enExample) 2009-04-11
US20040162251A1 (en) 2004-08-19
DE60225899D1 (de) 2008-05-15
JP4987022B2 (ja) 2012-07-25
DK1362600T3 (da) 2008-07-28

Similar Documents

Publication Publication Date Title
PT1362600E (pt) Utilização tópica de iscos de nf-kb para o tratamento da dermatite atópica
WO2002043652A3 (en) Anti-proliferative drugs
WO2001048190A3 (en) Therapeutic uses of lna-modified oligonucleotides
MXPA05002791A (es) Oligonucleotidos antivirales complementarios sin secuencia.
AU7445901A (en) Pharmaceutical compositions comprising cannabidiol derivatives
DE60038695D1 (de) Gegen bakterielle 16s und 23s rrnas gerichtete ungeladene antisense oligonukleotide und deren verwendungen
CA2265917A1 (en) Method for using oligonucleotides having modified cpg dinucleosides
WO2001081671A3 (en) Methods and fabrics for combating nosocomial infections
WO2001045679A3 (de) Verwendung von chemotherapeutika zur topischen behandlung
EP1576963A3 (en) Use of botulinum toxin in the treatment of pain due to an infection
EP1251126A3 (en) Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
WO2004096216A3 (en) Use of a topical medicament comprising riluzole
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
MY138883A (en) Use of asiatic acid for treatment of cencer
GB9902555D0 (en) Medicament
WO1999063978A3 (en) Methods of treating microbial infection and therapeutic formulations therefor
WO2003026563A3 (en) Conjugated anti-psychotic drugs and uses thereof
WO1999041364A3 (en) Compositions and methods for wound healing
WO2002102311A3 (en) Nanoparticles for treating targeted tissues and cells
WO2003099213A3 (en) Method for reducing platelet count
MXPA02010184A (es) Formulaciones topicas para el suministro transdermico de niacina y metodos para tratar hiperlipidemia.
WO1999056666A8 (en) The treatment of sexual dysfunction in certain patient groups
BR0115881A (pt) Emprego de compostos ciclohexanona substituìdos de 6-dimetilaminometil-1-fenil para a terapia da incontinência urinária
WO2000063348A3 (fr) Composition pharmaceutique comprenant des cellules nkt activees par des pim, et son utilisation en therapie
MXPA05008490A (es) Combinaciones que contienen imidazopiridinas y su uso en el tratamiento de enfermedades gastrointestinales inflamatorias.